|
Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children Clinical research trials and Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children. Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children clinical trial. Human subjects frequently get the finest healthcare available for their Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children  Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children
Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): Boehringer Ingelheim Pharmaceuticals ,
Synopsis: The purpose of this study is to determine the safety and tolerability of liquid formulation tipranavir together with low dose ritonavir in HIV-infected children and adolescents. Additionally, the study will provide information concerning the pharmacologic characteristics of tipranavir in this age group.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 2 Years/18 Years
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA - Males and females between 2 and 18 years of age - Confirmed diagnosis of HIV-1 infection - Viral load > 1500 RNA copies/mL - Acceptable screening laboratory values indicative of adequate baseline organ function - Signed informed consent prior to study participation from the patient or legal guardian - Ability to take medications and comply with requirements of the protocol EXCLUSION CRITERIA - Female patients of childbearing potential who: * have a positive serum pregnancy test at screening * are breast feeding * are planning on becoming pregnant * are not willing to use two methods of contraception - Active hepatitis B or C disease - Life expectancy <12 months - Patients who are unwilling to abstain from ingesting contraindicated medications and substances which may significantly affect plasma levels of the study medications - Active substance abuse - Use of investigational medications or vaccines within 28 days before study entry or during the trial - Requirement for any therapy for malignancy or immunomodulatory drug - Any active opportunistic infection within 28 days before study entry or other clinically significant findings that may compromise the outcome of the study - Patients with malabsorption, severe chronic diarrhea or vomiting - Evidence of symptoms of encephalopathy or developmental delay that would reduce compliance
Total Enrollment:
Location and Contact Information:
Texas Children's Hospital *Recruiting*
Houston, Texas, 77030
United States
Recruiting
Childrens Hospital of Los Angeles *Recruiting*
Los Angeles, California, 90027
United States
Recruiting
UMASS Memorial Medical Center *Recruiting*
Worcester, Massachusetts, 01655
United States
Recruiting
Baystate Medical Center *Recruiting*
Springfield, Massachusetts, 01199
United States
Recruiting
Rainbow Babies and Childrens Hospital *Recruiting*
Cleveland, Ohio, 44106
United States
Recruiting
Connecticut Children's Medical Center *Recruiting*
Hartford, Connecticut, 06106
United States
Recruiting
San Juan Hospital *Recruiting*
San Juan, , 00935
Puerto Rico
Recruiting
Los Angeles County - USC Medical Center *Recruiting*
Los Angeles, California, 90033
United States
Recruiting
Children's Memorial Hospital *Recruiting*
Chicago, Illinois, 60614
United States
Recruiting
St. Jude Children's Research Hospital *Recruiting*
Memphis, Tennessee, 38105
United States
Recruiting
Additional Information:
Study ID Numbers: BI 1182.14;
Study Start Date: February 2004
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00076999
Other Hiv Infections Studies:
1. Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy Adults
2. Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis carinii Pneumonia (PCP) in Patients with AIDS
3. Transfusion Infections Pediatric Prospective Study (TRIPPS)
4. Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
5. A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides
Related Studies:
Other HIV Infections Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Pharmacokinetics and Safety Study of Tipranavir in Combination with Low Dose Ritonavir in HIV-Infected Children
|
|
|
|
|
|
|
|
